Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.41 HKD
Change Today +0.03 / 7.89%
Volume 5.1M
8037 On Other Exchanges
Symbol
Exchange
Hong Kong
Berlin
As of 4:01 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

rui kang pharmaceutical grou (8037) Snapshot

Open
$0.38
Previous Close
$0.38
Day High
$0.42
Day Low
$0.38
52 Week High
08/19/14 - $1.11
52 Week Low
04/15/15 - $0.31
Market Cap
103.6M
Average Volume 10 Days
2.7M
EPS TTM
$-0.74
Shares Outstanding
252.7M
EX-Date
08/15/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RUI KANG PHARMACEUTICAL GROU (8037)

Related News

No related news articles were found.

rui kang pharmaceutical grou (8037) Related Businessweek News

No Related Businessweek News Found

rui kang pharmaceutical grou (8037) Details

Rui Kang Pharmaceutical Group Investments Limited, an investment holding company, is engaged in the research and development, manufacture, distribution, and sale of consumer cosmetics, health related and pharmaceutical products, health supplement wine, and dental materials and equipment in the People’s Republic of China and Hong Kong. It also trades in securities in Hong Kong; and manufactures and sells household commodities, as well as trades in household commodities and health related products. The company was formerly known as Longlife Group Holdings Limited and changed its name to Rui Kang Pharmaceutical Group Investments Limited in May 2014. Rui Kang Pharmaceutical Group Investments Limited was founded in 1996 and is based in Kowloon, Hong Kong.

479 Employees
Last Reported Date: 05/14/15
Founded in 1996

rui kang pharmaceutical grou (8037) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $486.0K
Chairman, Chairman of Nomination Committee an...
Total Annual Compensation: $1.7M
Compliance Officer, Executive Director and Me...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

rui kang pharmaceutical grou (8037) Key Developments

Rui Kang Pharmaceutical Seeks Acquisition

Rui Kang Pharmaceutical Group Investments Limited (SEHK:8037) has announced a follow-on equity of HKD 304.6 million. The funds will be used for business expansion, potential acquisitions and general working capital.

Rui Kang Pharmaceutical Group Investments Limited Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Rui Kang Pharmaceutical Group Investments Limited reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported turnover of HKD 33,453,000 against HKD 25,602,000 a year ago. Profit from operations was HKD 23,822,000 against loss from operations of HKD 23,822,000 a year ago. Profit before tax was HKD 7,307,000 against loss before tax of HKD 24,278,000 a year ago. Profit for the period attributable to equity holders of the company was HKD 7,281,000 against loss for the period attributable to equity holders of the company of HKD 24,327,000 a year ago. Basic and diluted per share was HKD 0.030 against basic and diluted loss per share of HKD 0.277 a year ago.

Rui Kang Pharmaceutical Group Investments Limited Provides Earnings Guidance for the Three Months Ended 31 March 2015

The board of directors of Rui Kang Pharmaceutical Group Investments Limited informed the shareholders of the company and potential investors that based on information currently available, the group is expected to record a net profit for the three months ended 31 March 2015 as compared to a net loss for the corresponding period in 2014. The Board considers that such expected profit was mainly attributable to the net gain on financial assets at fair value through profit or loss of approximately HKD 12 million for the three months ended 31 March 2015 as compared with the net loss on financial assets at fair value through profit or loss of approximately HKD 15 million during the corresponding period in 2014; and coupled with the effective cost control measures which led to a decrease in the administrative expenses and the selling and distribution expenses during the three months ended 31 March 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8037:HK $0.41 HKD +0.03

8037 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8037.
View Industry Companies
 

Industry Analysis

8037

Industry Average

Valuation 8037 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RUI KANG PHARMACEUTICAL GROU, please visit www.ruikang.com.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.